



## ASX MEDIA RELEASE

---

### Uscom New Non-Executive Board Appointment

**SYDNEY, Australia, Tuesday 23<sup>rd</sup> August 2018:** Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) announced the appointment of Brett Crowley as Non-executive Director of the Board of Directors of Uscom Limited. Mr Crowley will replace Sheena Jack who retires after 6 years on the Board.

Mr Crowley is a practicing solicitor and a former Partner of Ernst & Young in Hong Kong and Australia, and of KPMG in Hong Kong, and has worked in China establishing and managing a JV company there. Mr Crowley is an experienced chairman, finance director and company secretary of ASX-listed companies, and is a former Senior Legal Member of the NSW Civil and Administrative Tribunal. He has been the Uscom Secretary for the last 2 years.

Mr Crowley has over 30 years' experience, including China, advising companies on taxation, corporate strategy, international structuring, capital raising and commercial negotiations, and joins Mr Christian Bernecker and Rob Phillips on the Uscom Board.

Mr Crowley replaces Ms Sheena Jack, who has resigned as Uscom Non-executive Director after 6 years, to focus on her new role as CEO of HCF, one of Australia's largest Private Health Fund and Life Insurance Organisations.

Uscom CEO Associate Professor Rob Phillips said: *"Uscom's philosophy of employing a small and quality management team continues with the appointment of Mr Brett Crowley, our new Non-executive Director. Brett has corporate and operational experience in China and Hong Kong where he both lived and worked, and his international corporate secretarial experience is invaluable. Ms Sheena Jack's new role as CEO of HCF is a demanding one. Her insightful and experienced input to Uscom over the last 6 years steered the company through two acquisitions and expansion into global operations, and set us on a strategic growth trajectory. On behalf of the Board and all Uscom shareholders we express our thanks for her contribution and wish her well."*



## ASX MEDIA RELEASE

---

### About Uscom

**Uscom Limited (UCM)** is an ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

**The USCOM 1A** is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

**The Uscom BP+** is a supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations, trend measure progress over time, analyse pulse pressure waves and generate a summary report.

**Uscom SpiroSonic digital ultrasonic spirometers** are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary **SpiroReporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations, trend measure progress over time, analyse spirometry outputs and generate a summary report.

For more information, please visit: [www.uscom.com.au](http://www.uscom.com.au)

### Uscom Contacts

Rob Phillips  
Executive Chairman  
[rob@uscom.com.au](mailto:rob@uscom.com.au)

Brett Crowley  
Company Secretary  
[secretary@uscom.com.au](mailto:secretary@uscom.com.au)